Dixon DO - Search Results

1

Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop.

Albert JM, Ioannidis JP, Reichelderfer P, Conway B, Coombs RW, Crane L, Demasi R, Dixon DO, Flandre P, Hughes MD, Kalish LA, Larntz K, Lin D, Marschner IC, Muñoz A, Murray J, Neaton J, Pettinelli C, Rida W, Taylor JM, Welles SL. Albert JM, et al. Among authors: dixon do. Stat Med. 1998 Nov 15;17(21):2435-62. Stat Med. 1998. PMID: 9819838

2

Issues in the design and analysis of AIDS clinical trials.

Dixon DO, Albert JM. Dixon DO, et al. Cancer Treat Res. 1995;75:29-47. doi: 10.1007/978-1-4615-2009-2_2. Cancer Treat Res. 1995. PMID: 7640166 Review. No abstract available.

3

Relationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary Pneumocystis carinii prophylaxis.

Ioannidis JP, Dixon DO, McIntosh M, Albert JM, Bozzette SA, Schnittman SM. Ioannidis JP, et al. Among authors: dixon do. Control Clin Trials. 1999 Jun;20(3):253-66. doi: 10.1016/s0197-2456(98)00053-1. Control Clin Trials. 1999. PMID: 10357498

4

HIV vaccine trials: some design issues including sample size calculation.

Dixon DO, Rida WN, Fast PE, Hoth DF. Dixon DO, et al. J Acquir Immune Defic Syndr (1988). 1993 May;6(5):485-96. J Acquir Immune Defic Syndr (1988). 1993. PMID: 8483112 Clinical Trial.

5

A Bayesian model for evaluating specificity of treatment effects in clinical trials.

Simon RM, Dixon DO, Freidlin B. Simon RM, et al. Among authors: dixon do. Cancer Treat Res. 1995;75:155-75. doi: 10.1007/978-1-4615-2009-2_8. Cancer Treat Res. 1995. PMID: 7640162 Review. No abstract available.

6

Should data and safety monitoring boards share confidential interim data?

Dixon DO, Lagakos SW. Dixon DO, et al. Control Clin Trials. 2000 Feb;21(1):1-6; discussion 54-5. doi: 10.1016/s0197-2456(99)00042-2. Control Clin Trials. 2000. PMID: 10659999

7

Bayesian subset analysis in a colorectal cancer clinical trial.

Dixon DO, Simon R. Dixon DO, et al. Stat Med. 1992 Jan 15;11(1):13-22. doi: 10.1002/sim.4780110104. Stat Med. 1992. PMID: 1557569 Clinical Trial.

8

Multiple comparisons for relative risk regression: extension of the kappa-ratio method.

Dixon DO, Divine GW. Dixon DO, et al. Stat Med. 1987 Jul-Aug;6(5):591-7. doi: 10.1002/sim.4780060508. Stat Med. 1987. PMID: 3659669

9

Sample size considerations for studies comparing survival curves using historical controls.

Dixon DO, Simon R. Dixon DO, et al. J Clin Epidemiol. 1988;41(12):1209-13. doi: 10.1016/0895-4356(88)90025-x. J Clin Epidemiol. 1988. PMID: 3062140 Clinical Trial.

10

Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial.

Balevic SJ, Benjamin DK Jr, Powderly WG, Smith PB, Gonzalez D, McCarthy MW, Shaw LK, Lindsell CJ, Bozzette S, Williams D, Linas BP, Blamoun J, Javeri H, Hornik CP; ACTIV-1 IM Study Group. Balevic SJ, et al. JAMA Netw Open. 2024 Apr 1;7(4):e247615. doi: 10.1001/jamanetworkopen.2024.7615. JAMA Netw Open. 2024. PMID: 38662372 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

88 results

Search Page

Filters